Global Pediatric Vaccines Market By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), By Indication (Varicella, Diphtheria, Pertus

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,380	310 Pages	Allied Market Research	November, 2022	ALMR17652000

Best Price Guarantee
Price	from $4,380
Length	310 Pages
Publisher	Allied Market Research
Published Date	November, 2022
SKU	ALMR17652000

Global Pediatric Vaccines Market By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), By Indication (Varicella, Diphtheria, Pertussis and Tetanus, Influenza, Human Papilloma Virus, Measles, Mumps and Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Other Indications): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global pediatric vaccine market accounted for $2,1371.73 million in 2021, and is expected to reach $ 3,6390.99 million by 2031, registering a CAGR of 5.4% from 2022 to 2031.

Pediatric vaccine is a biological preparation that is administered to produce acquired immunity in children. Administration of vaccines aids to enhance immune response against a specific pathogen. Pediatric vaccinations play a key role in sustaining children health across different countries; hence, they are used in various national disease-prevention strategies. Owing to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Pediatric vaccinations are primarily provided to children of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.

It is estimated that pediatric vaccine market is expected to experience significant market growth during the forecast period as there has been surge in adoption in several countries across the globe in the national immunization programs. In addition, rise in prevalence of pneumococcal, influenza, and meningococcal disease in several countries has led to upsurge in demand for vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products are expected to impede the market growth. In contrast, rise in demand in emerging markets, increase in R&D activities to develop new vaccines, and surge in healthcare spending are anticipated to provide significant growth opportunities for the pediatric vaccine market.

The pediatric vaccine market is segmented on the basis of type, technology, indication, and region. On the basis of type, the market is bifurcated into monovalent and multivalent. Depending on technology, it is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. By indication, it is classified into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global pediatric vaccine market. Key companies profiled in the report include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global paediatric vaccine market analysis from 2021 to 2031 to identify the prevailing global paediatric vaccine market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the global paediatric vaccine market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global global paediatric vaccine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technology

Live Attenuated Vaccines
Inactivated Vaccines
Toxoid Vaccines
Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines

By Type

Monovalent
Multivalent

By Indication

Varicella
Measles, Mumps and Rubella
Meningococcal Disease
Pneumococcal Disease
Polio
Rotavirus
Diphtheria, Pertussis and Tetanus
Influenza
Human Papilloma Virus
Other Indications

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA

Key Market Players

AstraZeneca Plc.
CSL Limited
Emergent BioSolutions Inc.
GlaxoSmithKline plc.
Johnson & Johnson
Merck & Co., Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi Aventis
Serum Institute of India Pvt. Ltd.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Monovalent; 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market share analysis by country; 4.3 Multivalent; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market share analysis by country
CHAPTER 5: GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 Live Attenuated Vaccines; 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market share analysis by country; 5.3 Inactivated Vaccines; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market share analysis by country; 5.4 Toxoid Vaccines; 5.4.1 Key market trends, growth factors and opportunities; 5.4.2 Market size and forecast, by region; 5.4.3 Market share analysis by country; 5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines; 5.5.1 Key market trends, growth factors and opportunities; 5.5.2 Market size and forecast, by region; 5.5.3 Market share analysis by country
CHAPTER 6: GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Varicella; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market share analysis by country; 6.3 Diphtheria, Pertussis and Tetanus; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market share analysis by country; 6.4 Influenza; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market share analysis by country; 6.5 Human Papilloma Virus; 6.5.1 Key market trends, growth factors and opportunities; 6.5.2 Market size and forecast, by region; 6.5.3 Market share analysis by country; 6.6 Measles, Mumps and Rubella; 6.6.1 Key market trends, growth factors and opportunities; 6.6.2 Market size and forecast, by region; 6.6.3 Market share analysis by country; 6.7 Meningococcal Disease; 6.7.1 Key market trends, growth factors and opportunities; 6.7.2 Market size and forecast, by region; 6.7.3 Market share analysis by country; 6.8 Pneumococcal Disease; 6.8.1 Key market trends, growth factors and opportunities; 6.8.2 Market size and forecast, by region; 6.8.3 Market share analysis by country; 6.9 Polio; 6.9.1 Key market trends, growth factors and opportunities; 6.9.2 Market size and forecast, by region; 6.9.3 Market share analysis by country; 7.0 Rotavirus; 7.0.1 Key market trends, growth factors and opportunities; 7.0.2 Market size and forecast, by region; 7.0.3 Market share analysis by country; 7.1 Other Indications; 7.1.1 Key market trends, growth factors and opportunities; 7.1.2 Market size and forecast, by region; 7.1.3 Market share analysis by country
CHAPTER 7: GLOBAL PEDIATRIC VACCINES MARKET, BY REGION: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 North America; 7.2.1 Key trends and opportunities; 7.2.2 North America Market size and forecast, by Type; 7.2.3 North America Market size and forecast, by Technology; 7.2.4 North America Market size and forecast, by Indication; 7.2.5 North America Market size and forecast, by country; 7.2.5.1 U.S.; 7.2.5.1.1 Key market trends, growth factors and opportunities; 7.2.5.1.2 Market size and forecast, by Type; 7.2.5.1.3 Market size and forecast, by Technology; 7.2.5.1.4 Market size and forecast, by Indication; 7.2.5.2 Canada; 7.2.5.2.1 Key market trends, growth factors and opportunities; 7.2.5.2.2 Market size and forecast, by Type; 7.2.5.2.3 Market size and forecast, by Technology; 7.2.5.2.4 Market size and forecast, by Indication; 7.2.5.3 Mexico; 7.2.5.3.1 Key market trends, growth factors and opportunities; 7.2.5.3.2 Market size and forecast, by Type; 7.2.5.3.3 Market size and forecast, by Technology; 7.2.5.3.4 Market size and forecast, by Indication; 7.3 Europe; 7.3.1 Key trends and opportunities; 7.3.2 Europe Market size and forecast, by Type; 7.3.3 Europe Market size and forecast, by Technology; 7.3.4 Europe Market size and forecast, by Indication; 7.3.5 Europe Market size and forecast, by country; 7.3.5.1 Germany; 7.3.5.1.1 Key market trends, growth factors and opportunities; 7.3.5.1.2 Market size and forecast, by Type; 7.3.5.1.3 Market size and forecast, by Technology; 7.3.5.1.4 Market size and forecast, by Indication; 7.3.5.2 France; 7.3.5.2.1 Key market trends, growth factors and opportunities; 7.3.5.2.2 Market size and forecast, by Type; 7.3.5.2.3 Market size and forecast, by Technology; 7.3.5.2.4 Market size and forecast, by Indication; 7.3.5.3 UK; 7.3.5.3.1 Key market trends, growth factors and opportunities; 7.3.5.3.2 Market size and forecast, by Type; 7.3.5.3.3 Market size and forecast, by Technology; 7.3.5.3.4 Market size and forecast, by Indication; 7.3.5.4 Italy; 7.3.5.4.1 Key market trends, growth factors and opportunities; 7.3.5.4.2 Market size and forecast, by Type; 7.3.5.4.3 Market size and forecast, by Technology; 7.3.5.4.4 Market size and forecast, by Indication; 7.3.5.5 Spain; 7.3.5.5.1 Key market trends, growth factors and opportunities; 7.3.5.5.2 Market size and forecast, by Type; 7.3.5.5.3 Market size and forecast, by Technology; 7.3.5.5.4 Market size and forecast, by Indication; 7.3.5.6 Rest of Europe; 7.3.5.6.1 Key market trends, growth factors and opportunities; 7.3.5.6.2 Market size and forecast, by Type; 7.3.5.6.3 Market size and forecast, by Technology; 7.3.5.6.4 Market size and forecast, by Indication; 7.4 Asia-Pacific; 7.4.1 Key trends and opportunities; 7.4.2 Asia-Pacific Market size and forecast, by Type; 7.4.3 Asia-Pacific Market size and forecast, by Technology; 7.4.4 Asia-Pacific Market size and forecast, by Indication; 7.4.5 Asia-Pacific Market size and forecast, by country; 7.4.5.1 China; 7.4.5.1.1 Key market trends, growth factors and opportunities; 7.4.5.1.2 Market size and forecast, by Type; 7.4.5.1.3 Market size and forecast, by Technology; 7.4.5.1.4 Market size and forecast, by Indication; 7.4.5.2 Japan; 7.4.5.2.1 Key market trends, growth factors and opportunities; 7.4.5.2.2 Market size and forecast, by Type; 7.4.5.2.3 Market size and forecast, by Technology; 7.4.5.2.4 Market size and forecast, by Indication; 7.4.5.3 India; 7.4.5.3.1 Key market trends, growth factors and opportunities; 7.4.5.3.2 Market size and forecast, by Type; 7.4.5.3.3 Market size and forecast, by Technology; 7.4.5.3.4 Market size and forecast, by Indication; 7.4.5.4 Australia; 7.4.5.4.1 Key market trends, growth factors and opportunities; 7.4.5.4.2 Market size and forecast, by Type; 7.4.5.4.3 Market size and forecast, by Technology; 7.4.5.4.4 Market size and forecast, by Indication; 7.4.5.5 South Korea; 7.4.5.5.1 Key market trends, growth factors and opportunities; 7.4.5.5.2 Market size and forecast, by Type; 7.4.5.5.3 Market size and forecast, by Technology; 7.4.5.5.4 Market size and forecast, by Indication; 7.4.5.6 Rest of Asia-Pacific; 7.4.5.6.1 Key market trends, growth factors and opportunities; 7.4.5.6.2 Market size and forecast, by Type; 7.4.5.6.3 Market size and forecast, by Technology; 7.4.5.6.4 Market size and forecast, by Indication; 7.5 LAMEA; 7.5.1 Key trends and opportunities; 7.5.2 LAMEA Market size and forecast, by Type; 7.5.3 LAMEA Market size and forecast, by Technology; 7.5.4 LAMEA Market size and forecast, by Indication; 7.5.5 LAMEA Market size and forecast, by country; 7.5.5.1 Brazil; 7.5.5.1.1 Key market trends, growth factors and opportunities; 7.5.5.1.2 Market size and forecast, by Type; 7.5.5.1.3 Market size and forecast, by Technology; 7.5.5.1.4 Market size and forecast, by Indication; 7.5.5.2 Saudi Arabia; 7.5.5.2.1 Key market trends, growth factors and opportunities; 7.5.5.2.2 Market size and forecast, by Type; 7.5.5.2.3 Market size and forecast, by Technology; 7.5.5.2.4 Market size and forecast, by Indication; 7.5.5.3 South Africa; 7.5.5.3.1 Key market trends, growth factors and opportunities; 7.5.5.3.2 Market size and forecast, by Type; 7.5.5.3.3 Market size and forecast, by Technology; 7.5.5.3.4 Market size and forecast, by Indication; 7.5.5.4 Rest of LAMEA; 7.5.5.4.1 Key market trends, growth factors and opportunities; 7.5.5.4.2 Market size and forecast, by Type; 7.5.5.4.3 Market size and forecast, by Technology; 7.5.5.4.4 Market size and forecast, by Indication
CHAPTER 8: COMPANY LANDSCAPE: 8.1. Introduction; 8.2. Top winning strategies; 8.3. Product Mapping of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Key developments
CHAPTER 9: COMPANY PROFILES: 9.1 AstraZeneca Plc.; 9.1.1 Company overview; 9.1.2 Company snapshot; 9.1.3 Operating business segments; 9.1.4 Product portfolio; 9.1.5 Business performance; 9.1.6 Key strategic moves and developments; 9.2 CSL Limited; 9.2.1 Company overview; 9.2.2 Company snapshot; 9.2.3 Operating business segments; 9.2.4 Product portfolio; 9.2.5 Business performance; 9.2.6 Key strategic moves and developments; 9.3 Emergent BioSolutions Inc.; 9.3.1 Company overview; 9.3.2 Company snapshot; 9.3.3 Operating business segments; 9.3.4 Product portfolio; 9.3.5 Business performance; 9.3.6 Key strategic moves and developments; 9.4 GlaxoSmithKline plc.; 9.4.1 Company overview; 9.4.2 Company snapshot; 9.4.3 Operating business segments; 9.4.4 Product portfolio; 9.4.5 Business performance; 9.4.6 Key strategic moves and developments; 9.5 Johnson & Johnson; 9.5.1 Company overview; 9.5.2 Company snapshot; 9.5.3 Operating business segments; 9.5.4 Product portfolio; 9.5.5 Business performance; 9.5.6 Key strategic moves and developments; 9.6 Merck & Co., Inc.; 9.6.1 Company overview; 9.6.2 Company snapshot; 9.6.3 Operating business segments; 9.6.4 Product portfolio; 9.6.5 Business performance; 9.6.6 Key strategic moves and developments; 9.7 Novavax, Inc.; 9.7.1 Company overview; 9.7.2 Company snapshot; 9.7.3 Operating business segments; 9.7.4 Product portfolio; 9.7.5 Business performance; 9.7.6 Key strategic moves and developments; 9.8 Pfizer Inc.; 9.8.1 Company overview; 9.8.2 Company snapshot; 9.8.3 Operating business segments; 9.8.4 Product portfolio; 9.8.5 Business performance; 9.8.6 Key strategic moves and developments; 9.9 Sanofi Aventis; 9.9.1 Company overview; 9.9.2 Company snapshot; 9.9.3 Operating business segments; 9.9.4 Product portfolio; 9.9.5 Business performance; 9.9.6 Key strategic moves and developments; 9.10 Serum Institute of India Pvt. Ltd.; 9.10.1 Company overview; 9.10.2 Company snapshot; 9.10.3 Operating business segments; 9.10.4 Product portfolio; 9.10.5 Business performance; 9.10.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 6. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 15. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION); TABLE 37. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 38. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 39. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 40. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 41. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 42. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 43. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 44. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 45. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 46. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 47. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 48. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 49. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 50. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 51. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 52. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 53. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 54. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 55. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 56. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 57. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 58. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 59. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 60. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 61. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 62. UK GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 63. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 64. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 65. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 66. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 67. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 68. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 69. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 70. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 71. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 72. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 73. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 74. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 75. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 76. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 77. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 78. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 79. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 80. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 81. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 82. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 83. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 84. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 85. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 86. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 87. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 88. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 89. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 90. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 91. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 92. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 93. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 94. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 95. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 96. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 97. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION); TABLE 98. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 99. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 100. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 101. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 102. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 103. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 104. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 105. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 106. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 107. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION); TABLE 108. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION); TABLE 109. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION); TABLE 110.ASTRAZENECA PLC.: COMPANY SNAPSHOT; TABLE 111.ASTRAZENECA PLC.: OPERATING SEGMENTS; TABLE 112.ASTRAZENECA PLC.: PRODUCT PORTFOLIO; TABLE 113.ASTRAZENECA PLC.: NET SALES; TABLE 114.ASTRAZENECA PLC.: KEY STRATERGIES; TABLE 115.CSL LIMITED: COMPANY SNAPSHOT; TABLE 116.CSL LIMITED: OPERATING SEGMENTS; TABLE 117.CSL LIMITED: PRODUCT PORTFOLIO; TABLE 118.CSL LIMITED: NET SALES; TABLE 119.CSL LIMITED: KEY STRATERGIES; TABLE 120.EMERGENT BIOSOLUTIONS INC.: COMPANY SNAPSHOT; TABLE 121.EMERGENT BIOSOLUTIONS INC.: OPERATING SEGMENTS; TABLE 122.EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO; TABLE 123.EMERGENT BIOSOLUTIONS INC.: NET SALES; TABLE 124.EMERGENT BIOSOLUTIONS INC.: KEY STRATERGIES; TABLE 125.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT; TABLE 126.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS; TABLE 127.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO; TABLE 128.GLAXOSMITHKLINE PLC.: NET SALES; TABLE 129.GLAXOSMITHKLINE PLC.: KEY STRATERGIES; TABLE 130.JOHNSON & JOHNSON: COMPANY SNAPSHOT; TABLE 131.JOHNSON & JOHNSON: OPERATING SEGMENTS; TABLE 132.JOHNSON & JOHNSON: PRODUCT PORTFOLIO; TABLE 133.JOHNSON & JOHNSON: NET SALES; TABLE 134.JOHNSON & JOHNSON: KEY STRATERGIES; TABLE 135.MERCK & CO., INC.: COMPANY SNAPSHOT; TABLE 136.MERCK & CO., INC.: OPERATING SEGMENTS; TABLE 137.MERCK & CO., INC.: PRODUCT PORTFOLIO; TABLE 138.MERCK & CO., INC.: NET SALES; TABLE 139.MERCK & CO., INC.: KEY STRATERGIES; TABLE 140.NOVAVAX, INC.: COMPANY SNAPSHOT; TABLE 141.NOVAVAX, INC.: OPERATING SEGMENTS; TABLE 142.NOVAVAX, INC.: PRODUCT PORTFOLIO; TABLE 143.NOVAVAX, INC.: NET SALES; TABLE 144.NOVAVAX, INC.: KEY STRATERGIES; TABLE 145.PFIZER INC.: COMPANY SNAPSHOT; TABLE 146.PFIZER INC.: OPERATING SEGMENTS; TABLE 147.PFIZER INC.: PRODUCT PORTFOLIO; TABLE 148.PFIZER INC.: NET SALES; TABLE 149.PFIZER INC.: KEY STRATERGIES; TABLE 150.SANOFI AVENTIS: COMPANY SNAPSHOT; TABLE 151.SANOFI AVENTIS: OPERATING SEGMENTS; TABLE 152.SANOFI AVENTIS: PRODUCT PORTFOLIO; TABLE 153.SANOFI AVENTIS: NET SALES; TABLE 154.SANOFI AVENTIS: KEY STRATERGIES; TABLE 155.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT; TABLE 156.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS; TABLE 157.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO; TABLE 158.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES; TABLE 159.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.GLOBAL PEDIATRIC VACCINES MARKET SEGMENTATION; FIGURE 2.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031; FIGURE 3.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.GLOBAL PEDIATRIC VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 12.GLOBAL PEDIATRIC VACCINES MARKET,BY TYPE,2021(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MONOVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MULTIVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 15.GLOBAL PEDIATRIC VACCINES MARKET,BY TECHNOLOGY,2021(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIVE ATTENUATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 17.COMPARATIVE SHARE ANALYSIS OF INACTIVATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOXOID VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 20.GLOBAL PEDIATRIC VACCINES MARKET,BY INDICATION,2021(%); FIGURE 21.COMPARATIVE SHARE ANALYSIS OF VARICELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DIPHTHERIA, PERTUSSIS AND TETANUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INFLUENZA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HUMAN PAPILLOMA VIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 25.COMPARATIVE SHARE ANALYSIS OF MEASLES, MUMPS AND RUBELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 26.COMPARATIVE SHARE ANALYSIS OF MENINGOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 27.COMPARATIVE SHARE ANALYSIS OF PNEUMOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 28.COMPARATIVE SHARE ANALYSIS OF POLIO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 29.COMPARATIVE SHARE ANALYSIS OF ROTAVIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%); FIGURE 31.GLOBAL PEDIATRIC VACCINES MARKET BY REGION,2021; FIGURE 32.U.S. GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 33.CANADA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 34.MEXICO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 35.GERMANY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 36.FRANCE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 37.UK GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 38.ITALY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 39.SPAIN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 40.REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 41.CHINA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 42.JAPAN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 43.INDIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 44.AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 45.SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 46.REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 47.BRAZIL GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 48.SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 49.SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 50.REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION); FIGURE 51. TOP WINNING STRATEGIES, BY YEAR; FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT; FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY; FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 55.COMPETITIVE DASHBOARD; FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS; FIGURE 57.ASTRAZENECA PLC..: NET SALES ($MILLION); FIGURE 58.CSL LIMITED.: NET SALES ($MILLION); FIGURE 59.EMERGENT BIOSOLUTIONS INC..: NET SALES ($MILLION); FIGURE 60.GLAXOSMITHKLINE PLC..: NET SALES ($MILLION); FIGURE 61.JOHNSON & JOHNSO